AKT1 and cancer: Genetic alterations in FGFR2, including gene amplification, mutations or rearrangements may dysregulate the FGF signaling pathway, influence the development and progression of various cancers by activating the downstream PI3K–AKT and MAPK–ERK pathways [21].